Background The reporting interval is the incremental value chosen in reporting analyte concentration. Reporting intervals for different analytes are often inappropriately narrow, when analytical imprecision and biological variability are considered.
Introduction
The reporting interval is the incremental value chosen in reporting changes in analyte concentration. For sodium, this increment is 1mmol/L (e.g. 130 to 131mmol/L); for potassium, it is 0.1mmol/L (e.g. 4.2 to 4.3 mmol/L). Ideally, the reporting interval chosen should be such that it only registers a change when a real change is likely to have occurred.
In clinical practice, we are often confronted with the problem of whether an apparent change in analyte concentration is real and a re£ection of patient pathology, or simply a re£ection of the analytical imprecision of the assay and the innate biological variability within the individual person. 1, 2 It has been our subjective impression that reporting intervals for di¡erent analytes are often inappropriately narrow, when analytical imprecision and biological variability are considered. From an analytical viewpoint, it is apparent that the size of the reporting interval for any analyte should be determined by the imprecision for that analyte. There is little literature indicating a scienti¢c or statistical foundation to justify the widely used reporting intervals in laboratory practice. Rather, these have been developed on empirical, intuitive grounds.
In this paper, we use a statistics-based approach to de¢ne appropriate reporting intervals for analytes.We are only considering changes due to analytical imprecision and not biological variation, thus the intervals we identify should be considered as the lower limit to their true length. Our method is robust and readily applicable in all laboratories, for all analytes.
Methods
Consider the example in Fig. 1 , in which the theoretical distributions of assay results are shown for ferritin for three samples with mean concentrations of 60, 65 and 80 mg/L. The distribution has a standard deviation (s) of 4.5 mg/L, a value typical of those obtained in clinical biochemistry laboratories. Obviously, the population distributions corresponding to concentrations of 60 and 65 mg/L have a considerably greater overlap than the population distributions corresponding to concentrations of 60 and 80 mg/L.
Original Article
Deciding whether samples with measured concentrations of 60 and 65 mg/L are truly di¡erent is problematic. What objective criteria can be used to de¢ne what reporting interval should be used?
It is accepted that the population distribution of all possible results obtained in an analytical process is described using a normal or Gaussian distribution. Let x A and x B represent the results of measurements on two successive samples (A, B) for a patient. Their di¡erence can be evaluated using the following equation: 3
where z is referred to a standard normal distribution. If one assumes that the two values are independent, and the underlying variance (s 2 ) is the same for the ¢rst and second measurements, then equation 1 simpli¢es to:
A given critical di¡erence between consecutive sample results can then be calculated using equation 2. Our null hypothesis will be that observations x A and x B will be the same and we will base our evaluation on a two-sided test of signi¢cance as the second observation may be either greater or less than the ¢rst observation. Thus:
. If we want 95% certainty that the two results are di¡erent, then z ¼1.96 and jx A À x B j52.77s. . If we want 50% certainty that the two results are di¡erent then, z&0.67 and jx A À x B j50.954 s.
Use of a reporting interval with a 50% con¢dence level of the two results being the same or di¡erent is the most pragmatically useful course.We suggest use of a reporting interval slightly wider than the derived 50% value (RI 50 ). This would mean that a change in result is more likely to be real than an artefact of measurement. Analytical data were collected from routine internal quality control results generated over a 4-month period. The analytes studied and instrumentation used are shown in Tables 1 and 2. Quality control material used for general chemistry was Chem Trak Plus (Medical Analysis Systems, Camarillo CA, USA) and for immunoassay was Lyphochek (Bio-Rad Laboratories, Irvine CA, USA).
Results
Using the procedures described above, we calculated the reporting intervals that are necessary at 95% and 50% con¢dence levels that two results are truly analytically di¡erent. These results are shown in Tables 1 and 2. In additional columns, we show the usual reporting intervals at the indicated individual analyte concentrations and whether they meet the criteria for 50% con¢dence, as de¢ned above, that the two results are indeed analytically di¡erent. A number of important analytes strictly fail to meet the desirable reporting interval criteria at at least one analyte concentration.
None of the general chemistry analytes shown in Table 1 met the criteria for 95% con¢dence that two results were truly analytically di¡erent, although creatinine, potassium and triglyceride came close. Even at the 50% con¢dence level, 11 of 24 general chemistry analytes failed at all analyte concentrations tested, and some important analytes failed to meet the criteria by a substantial margin. For example, calcium at a concentration of 2.95 mmol/L required a change in reporting interval length of 0.048 mmol/L for 50% con¢dence that the two results were analytically di¡erent. Only 7 of the 24 analytes met the RI 50 criteria at all concentrations tested, and a further 6 met the criteria at one concentration only.
It should be noted that creatinine met the 50% criteria at both concentrations if reporting was in mmol/L, but failed at both concentrations if reported in mmol/L.
None of the analytes measured by immunoassay and shown in Table 2 met the criteria for 95% con¢dence of a real change, although the lowest concentrations of carbamazepine and prostate-speci¢c antigen came close. Only 6 of 22 analytes met the RI 50 criteria at all concentrations, and 13 of 22 analytes failed at all concentrations, some by a wide margin. Extreme examples are cortisol, which at a concentration of 550 nmol/L required a change of 35 nmol/L to be 50% certain that a real analytical change had 1.0 mU/L N 2 mU/L *Reporting intervals have been rounded to 2-digit accuracy. **Interpretation as to whether analytes meet the RI 50 criteria has been applied very strictly, but where the RI 50 is only marginally greater than the usual reporting interval it is recommended that current practice be maintained. AFP, afetoprotein; CEA, carcinoembryonic antigen; CRP, C-reactive protein; hs-CRP, high-sensitivity CRP; FSH, follicle-stimulating hormone; hCG, human chorionic gonadotrophin; LH, luteinizing hormone; PSA, prostate-specific antigen; TSH, thyroid-stimulating protein; RIA, radioimmunoassay.
occurred, and oestradiol, which at a concentration of 645 pmol/L required a change of 48 pmol/L to meet the RI 50 criteria.
Discussion
Whilst many of the general chemistry analytes shown in Table 1 meet the objective criteria we have derived, or only marginally exceed the RI 50 -derived interval, some important analytes failed to meet the criteria by a signi¢cant margin. A similar pattern was seen amongst the analytes measured by immunoassay, as shown in Table 2 , and some analytes failed to meet the criteria by a large margin. Clearly the appropriateness of reporting interval chosen is highly dependent upon analyte concentration. The implication of this work is that we need to review both how we report analyte concentrations or activities and how we interpret results. Whilst every analyte is deserving of comment, we limit our discussion to a few selected analytes of particular concern.
Calcium is an important case. Many patients with borderline hypercalcaemia may be investigated, especially for malignancy or hyperparathyroidism. The potential to over-interpret data here is signi¢cant. Our data suggest that calcium concentration should be reported in wider intervals than at present, and that an interval as wide as 0.05 mmol/L may be necessary.
If creatinine is reported in SI units (i.e. mmol/L), then assay precision is acceptable for reporting in increments of 0.01mmol/L. However, many laboratories report in mmol/L and in increments of only 1 mmol/L. This is inappropriate, and has the potential to lead to over-interpretation. 4 Our data suggest that, within the reference interval, reporting in increments of 5 mmol/L is the minimum acceptable, and at higher concentrations 10 mmol/L (0.01mmol/L) is the appropriate increment.
Clearly, the speci¢c RI 50 and RI 95 values may be in£uenced by the number of signi¢cant ¢gures in the reported standard deviation. In our calculations we have used the principle of reporting to two signi¢cant ¢gures only, and this has required some rounding-o¡ of numbers. Changing the number of signi¢cant ¢gures from three to two has the potential to distort the reporting interval calculation by only 5% so is of minor importance.
A number of analytes measured by immunoassay show gross discrepancies between desirable and actual reporting intervals.
Cortisol concentrations are of signi¢cance in two clinical settings in particular. The ¢rst of these is following the short Synacthen stimulation test for investigation of possible Addison's disease (cortisol de¢ciency). Most laboratories quote a sharply de¢ned cut-o¡ value, which may be 500 or 600 nmol/L, as being consistent with normal adrenal function. 5, 6 Because clinicians tend to have a very literal belief in laboratory numbers, small apparent changes in cortisol concentration can be given an undeserved signi¢cance.
At the other extreme of adrenal function, cortisol is measured as part of the overnight dexamethasone suppression test for investigation of Cushing's syndrome (cortisol excess). There is considerable confusion as to appropriate morning cortisol concentrations following dexamethasone, with values between 28 and 138 nmol/L being variously reported as appropriate decision levels. 7, 8 This variability probably re£ects lack of understanding of the cyclicity of Cushing's disease. 9 Whichever decision value is chosen, it is clear that, even at these low concentrations of cortisol, reporting intervals should be substantially wider than those currently used. It may be appropriate for cortisol, in particular, to quote an intermediate zone where the signi¢cance is not clear-cut, rather than the sharp demarcation in values as is current practice in most laboratories.
Measurement of high-sensitivity C-reactive protein (hs-CRP) is advocated as an index of cardiovascular risk. Based simply on the analytical performance of the assay, it is apparent that reporting intervals are too narrow. When the substantial biological variability is added to the considerations, 2 the validity of o¡ering hs-CRP measurement for individual risk assessment must be questioned.
Our suggestions that reporting intervals be changed are based solely upon objective data, using modern instrumentation showing an analytical performance that is unremarkable in modern laboratories. Our proposals are based solely upon analytical performance without any consideration of biological variability which will tend to cause even greater £uctuations, unrelated to patient pathology, in reported analyte concentration.
The ISO document 17025, 10 which is the current standard in Australia and many other countries for all accredited pathology laboratories, refers to'estimation of uncertainty of measurement'. Whilst reporting uncertainty of measurement is not compulsory at present, it is likely to be so in the future. We suggest that derivation of reporting interval as we describe here may be of considerable value in this context.
